Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Director comp.
LadRx Corp (CYTR) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K/A Quarterly results
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/28/2023 ARS Form ARS - Annual Report to Security Holders:
07/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
07/17/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Certificate of Amendment of Restated Certificate of Incorporation of LADRX Corporation",
"LadRx Announces Reverse Stock Split"
04/14/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
03/20/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A ARMISTICE CAPITAL, LLC reports a 10% stake in LadRx Corporation
12/30/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
09/23/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and ...
Docs: "Certificate of Amendment of Restated Certificate of Incorporation of CytRx CORPORATION CytRx Corporation , a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: 1. The original Certificate of Incorporation of this Corporation was filed with the Secretary of State of Delaware on February 28, 1985. 2. The Restated Certificate of Incorporation of this Corporation was filed with the Secretary of State of Delaware on November 15, 2007 . 3. The Certificate of Incorporation was further amended by Certificates of Amendment of Restated Certificate of Incorporation of CytRx Corporation, filed with the Secretary of State of Delaware on July 2, 2008, July 8, 2011, May 15, 2012, October 31, 2017, and March 16, 2022. 4...",
"CytRx Corporation Relaunches as LadRx Corporation"
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/28/2022 3 Claiborne Cary J (Director) has filed a Form 3 on CYTRX CORP
07/28/2022 D/A Form D/A - Notice of Exempt Offering of Securities: [Amend]
07/27/2022 8-K Quarterly results
06/16/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/16/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/16/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
06/03/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
06/02/2022 8-K Quarterly results
05/19/2022 8-K Quarterly results
05/19/2022 8-A12G Form 8-A12G - Registration of securities [Section 12(g)]:
05/12/2022 10-Q Quarterly Report for the period ended March 31, 2022
03/28/2022 EFFECT Form EFFECT - Notice of Effectiveness:
03/25/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
03/23/2022 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
03/23/2022 10-K Annual Report for the period ended December 31, 2021
03/21/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress"
03/16/2022 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "CERTIFICATE OF AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION OF CYTRX CORPORATION CytRx Corporation , a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: FIRST: The Restated Certificate of Incorporation of the Corporation is hereby amended by deleting in its entirety the Fourth Article and by replacing it with the following: “FOURTH. The total number of shares of all classes of stock that the corporation shall have the authority to issue is Sixty-Three Million Two Hundred Twenty-Seven Thousand Two-Hundred Seventy-Three , of which Sixty-Two Million Three Hundred Ninety-Three Thousand Nine Hundred Forty shall be common stock, par value $0.001 per share , and Eight Hundred Thirty-Three Thousand ..."
03/10/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Believes Integration Will Bring Enhanced Efficiency and Simplicity to the Company’ s Structure Notes the Company Will Fold Centurion into CytRx"
02/17/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
02/17/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "FAQ on Issuance of Shares to Armistice Capital and Special Meeting of Shareholders to Approve Increase in Authorized Shares Why did CytRx issue common and preferred shares to Armistice Capital? Following the announcement from Orphazyme in June 2021 that arimoclomol for Niemann-Pick Disease had not been granted FDA approval, the Board determined that a lack of action to raise additional capital to provide the Company financial flexibility at a critical time would have prevented them from complying with their fiduciary duties as directors of the Company. Since the Company did not have sufficient authorized common shares, CytRx entered into the Securities Purchase Agreement with Armistice Capital Master Fund, Ltd. , pursuant to which we issued and sold to Armistice, in a registered direct off..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy